Blarcamesine Shows Promise in Slowing Alzheimer’s Progression
Recent findings from Anavex Life Sciences reveal encouraging results for their investigational therapy,
blarcamesine, in treating early-stage Alzheimer disease (AD). A phase 2b/3
trial demonstrated significant reductions in pathological amyloid-ß levels in
plasma among patients administered the drug. This suggests that blarcamesine
could be an effective treatment in slowing cognitive decline associated with AD.
Anavex, a company focused on developing novel therapies for central nervous system
diseases, has shown through this study that blarcamesine has a notable impact
on biomarkers linked to neurodegeneration. The trial’s data indicated a
significant slowing in the rate of pathological brain atrophy as observed in
MRI scans. This positions blarcamesine as a potentially groundbreaking therapy
for patients suffering from early symptoms of AD.
The trial, which was a double-blind, placebo-controlled, and multicenter study, enrolled 508
participants from five countries. Participants were randomized to receive
either blarcamesine or a placebo daily over a period of 48 weeks. The primary
endpoints measured were cognitive and functional efficacy through validated
scales such as the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog)
and the Alzheimer’s Disease Cooperative Study-Activities of Daily Living
(ADCS-ADL).
Results showed a significant difference between the treatment and placebo groups. The
least-squares mean change from baseline to 48 weeks for ADAS-Cog was -1.783,
indicating a slowing in cognitive decline (P = .0226). Additionally, the
Clinical Dementia Rating Scale Sum of Boxes revealed further positive outcomes,
with a least-squares difference of -0.456 (P = .0175).
According to Anavex Life Sciences, safety profiles for blarcamesine were also promising. The most common
adverse event was mild to moderate dizziness, occurring transiently in a
majority of participants during the titration phase.
Anavex Life Sciences’ CEO, Christopher U Missling, PhD, expressed optimism about the
findings, emphasizing the potential of blarcamesine as an orally administered
treatment option for Alzheimer’s disease.
These results mark a significant milestone for Anavex, as they continue their efforts to provide
innovative solutions for neurodegenerative diseases. Refer to this article for related information.
Like their page on https://www.facebook.com/AnavexLifeSci/